Methods of treating egfrviii expressing glioblastomas

Patent metadata

Field	Value
Publication number	US-2025034229-A1
Application number	US-202418912410-A
Country	US
Kind code	A1
Filing date	Oct 10, 2024
Priority date	Apr 6, 2018
Publication date	Jan 30, 2025
Grant date	—

Abstract

Methods are provided for treating a subject for an EGFRvIII expressing glioblastoma. The methods of the present disclosure involve administering to the subject a molecular circuit that is primed by EGFRvIII to induce one or more encoded therapeutics specific for one or more antigens expressed by the glioblastoma. Nucleic acids containing sequences encoding all or portions of such circuits are also provided, as well as cells, expression cassettes and vectors that contain such nucleic acids. Also provided are kits for practicing the described methods.

First claim

1 . A method of treating a subject for an epidermal growth factor receptor variant III (EGFRvIII) positive glioblastoma, the method comprising:
administering to the subject an immune cell genetically modified with:
(a) a nucleic acid sequence encoding a binding triggered transcriptional switch (BTTS) that binds to EGFRvIII;
(b) a nucleic acid sequence encoding an antigen-specific therapeutic that binds to a killing antigen expressed by the glioblastoma; and
(c) a regulatory sequence operably linked to (b) that is responsive to the BTTS;
wherein binding of the BTTS to EGFRvIII activates expression of the antigen-specific therapeutic which binds the killing antigen thereby inducing killing of glioblastoma cells expressing the killing antigen.

2 . The method according to claim 1 , wherein the EGFRvIII positive glioblastoma comprises cells that express either EGFRvIII or the killing antigen.

3 . The method according to claims 1 , wherein the glioblastoma comprises cells that express both EGFRvIII and the killing antigen.

4 . The method according to claim 1 , wherein the killing antigen is expressed by all cells of the glioblastoma.

5 . The method according to claim 1 , wherein the killing antigen is expressed by non-glioblastoma cells in the subject.

6 . The method according to claim 1 , wherein less than 95% of the glioblastoma cells express EGFRvIII.

7 . The method according to claim 1 , wherein the killing antigen is selected from the group consisting of: Ephrin type-A receptor 2 (EphA2), Ephrin type-A receptor 3 (EphA3), Interleukin-13 receptor subunit alpha-1 (IL13RA1), Interleukin-13 receptor subunit alpha-2 (IL13RA2), Epidermal growth factor receptor (EGFR) and erb-b2 receptor tyrosine kinase 2 (ERBB2).

8 . The method according to claim 1 , wherein the antigen-specific therapeutic, when expressed, is expressed on the surface of the immune cell.

9 . The method according to claim 8 , wherein the antigen-specific therapeutic is a chimeric antigen receptor (CAR) or a T cell receptor (TCR).

10 . The method according to claim 1 , wherein the antigen-specific therapeutic, when expressed, is secreted by the immune cell.

11 - 39 . (canceled)

40 . An immune cell genetically modified with:
(a) a nucleic acid sequence encoding a binding triggered transcriptional switch (BTTS) that binds to EGFRvIII; (b) a nucleic acid sequence encoding a tandem chimeric antigen receptor (CAR) or a T cell receptor (TCR), wherein the tandem CAR or TCR comprises a first binding domain that recognizes Ephrin type-A receptor 2 (EphA2) and a second binding domain that recognizes IL-13 receptor α2 (IL-13Rα2); and (c) a regulatory sequence operably linked to (b) that is responsive to the BTTS;
wherein binding of the BTTS to EGFRvIII on EGFRvIII positive glioblastoma cells activates expression of the tandem CAR or TCR, which binds to EphA2 and/or IL-13Rα2 in the EGFRvIII positive glioblastoma and induces killing of tumor cells in an EGFRvIII positive glioblastoma.

41 . The immune cell according to claim 40 , wherein the BTTS is a SynNotch polypeptide.

42 . The immune cell according to claim 40 , wherein the immune cell is a lymphoid cell.

43 . The immune cell according to claim 42 , wherein the lymphoid cell is selected from the group consisting of: a T lymphocyte, a B lymphocyte and a Natural Killer cell.

44 . The immune cell of claim 40 , wherein the immune cell is a cytotoxic T cell.

45 . The immune cell of claim 40 , wherein the BTTS comprise:
an extracellular domain that comprises binding domains that bind to EGFRvIII; a transmembrane domain one or more protease cleavage domains; and a transcriptional activator,
wherein binding of the extracellular domain to EGFRvIII on EGFRvIII positive glioblastoma cells results in cleavage of the BTTS at the one or more protease cleavage domains to release the transcriptional activator, and wherein the released transcriptional activator binds to the regulatory sequence of (c) and activates expression of the tandem chimeric antigen receptor (CAR) or T cell receptor (TCR).

46 . The immune cell of claim 40 , wherein the nucleic acid sequence of (b) encodes a tandem CAR.

Assignees

• Univ California

Inventors

• Lim Wendell A
• Okada Hideho
• Roybal Kole T
• Choe Joseph H
• Watchmaker Payal B

Classifications

• C07K2318/20

  Antigen-binding scaffold molecules wherein the scaffold is not an immunoglobulin variable region or antibody mimetics · CPC title

• A61K40/4204

  Epidermal growth factor receptors [EGFR] · CPC title

• A61K40/422

  Ephrin Receptors [Eph] · CPC title

• A61K40/31

  Chimeric antigen receptors [CAR] · CPC title

• A61K40/11

  T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells · CPC title